SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) today announced significant
initial results of "House Rules," its national direct-to-consumer
(DTC) campaign with celebrity spokeswoman Annie Murphy, aimed at broadening awareness and
driving uptake of its hormone-free
contraceptive, Phexxi® (lactic acid,
citric acid and potassium bitartrate) vaginal gel.
"Early metrics powerfully demonstrate that our "House Rules"
campaign is effectively reaching our target audience, especially
women who are beyond hormones," said Saundra Pelletier, Chief Executive Officer of
Evofem. "We look forward to the ongoing impact of this
campaign to raise awareness of Phexxi for hormone-free
contraception, recognizing that already 29% of new Phexxi
prescriptions are conversions from pill users and 7% are
conversions from ring and patch users."
The "House Rules" DTC campaign, with 2 billion media impressions
to date, has resulted in a 263% increase in visitors to Phexxi.com,
and impacted key metrics including:
- A 71% increase in ex-factory sales of Phexxi (unit shipments to
wholesalers) in September versus August
2021.
- More than 5,100 women have begun using Phexxi since the launch
of the "House Rules" campaign, driving a 56% increase in new
patient starts in September versus August
2021.
- More than 2,800 women booked telehealth visits in the first
three weeks of the campaign, a 4x increase over the three week
period pre-launch.
- More than 8,900 Phexxi units were dispensed
in September 2021, a 41% increase over the prior month,
and total monthly prescriptions grew 45% to 7,839.
- 34% increase in new healthcare providers prescribing Phexxi
in September versus August 2021.
Over 9,400 healthcare providers have written Phexxi since the
product launched in September
2020.
Launched on September 9, 2021, the
"House Rules" campaign highlights the contraceptive journey of
millions of women, like Annie
Murphy, who are tired of dealing with the side effects of
hormones in their birth control, like depression, mood swings, and
irritability, thinking there was something wrong with
them.
Watch the "House Rules" commercial and Annie's birth control
story on demand on YouTube. Join the conversation on social
media, including Instagram
(@Phexxi and @EvofemBiosciences), Facebook
(@Phexxi and @Evofem), and Twitter (@Evofem).
About Phexxi
Phexxi is an on-demand method of birth control used to prevent
pregnancy. Phexxi is not effective when used after sex. For
more information about Phexxi, talk to your healthcare provide and
see full Product Information at www.phexxi.com.
Important Safety Information
- Rare cases (0.36%) of bladder and kidney infections have been
reported. If you have a history of urinary tract problems that keep
coming back, you should not use Phexxi.
- Contact your healthcare provider if you are experiencing
genitourinary side effects such as vaginal burning, itching,
discharge, genital discomfort (including in male partners), yeast
infection, urinary tract infection or bacterial vaginosis.
- Phexxi does not protect against sexually transmitted
infections, including HIV.
Please report side effects by contacting Evofem Biosciences
toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088
or www.fda.gov/medwatch.
Intended for United States residents only.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is developing and commercializing
innovative products to address unmet needs in women's sexual
and reproductive health, including hormone-free, woman-controlled
contraception and protection from certain sexually transmitted
infections (chlamydia and gonorrhea). Learn more
at evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Forward-Looking Statements
This press release includes
"forward-looking statements," within the meaning of the safe harbor
for forward-looking statements provided by Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995 including, without
limitation, statements related to the ongoing impact of the "House
Rules" campaign over the coming year. Various factors could cause
actual results to differ materially from those discussed or implied
in the forward-looking statements, and you are cautioned not to
place undue reliance on these forward-looking statements, which are
current only as of the date of this press release. Each of these
forward- looking statements involves risks and uncertainties.
Important factors that could cause actual results to differ
materially from those discussed or implied in the forward-looking
statements, or that could impair the value of Evofem Biosciences'
assets and business, are disclosed in the Company's SEC filings,
including its Annual Report on Form 10-K for the year
ended December 31, 2020 filed with the SEC on March
4, 2021. All forward-looking statements are expressly qualified in
their entirety by such factors. The Company does not undertake any
duty to update any forward-looking statement except as required by
law.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/house-rules-delivers-strong-initial-results-and-drives-phexxi-growth-301404476.html
SOURCE Evofem Biosciences, Inc.